Gardier R W, Peters J A
Arch Int Pharmacodyn Ther. 1984 Jan;267(1):35-45.
Functional tolerance was demonstrated to the antihypertensive effect of chlorisondamine Cl (Ecolid), a noncompetitive autonomic ganglion blocking agent, when administered chronically in increasing doses to spontaneously hypertensive rats (SHR), and normotensive Wistar-Kyoto (WKY) rats. Concomitant administration of atropine SO4 restored the hypotensive response to chlorisondamine without increasing its serum concentration. Atropine had no effect on the blood pressure of chlorisondamine-naive animals. No qualitative differences in therapeutic response were observed between the SHR and WKY rats. The results support the hypothesis that tolerance to the antihypertensive action of ganglionic blocking agents may be mediated by an activation of an alternate compensatory sympathetic ganglionic muscarinic pathway. It is speculated that this secondary pathway does not contribute to the hypertension in the SHR model.
当以递增剂量长期给予自发性高血压大鼠(SHR)和正常血压的Wistar-Kyoto(WKY)大鼠时,已证明对非竞争性自主神经节阻断剂氯异吲哚铵(Ecolid)的降压作用产生了功能性耐受。同时给予硫酸阿托品可恢复对氯异吲哚铵的降压反应,而不增加其血清浓度。阿托品对未用过氯异吲哚铵的动物血压无影响。在SHR和WKY大鼠之间未观察到治疗反应的定性差异。这些结果支持这样的假设,即对神经节阻断剂降压作用的耐受可能是由交替的代偿性交感神经节毒蕈碱途径的激活介导的。据推测,这条次要途径在SHR模型中对高血压无影响。